Effect of mannan-reduced gold nanoparticles on prostate cancer cells
Is this your thesis?
This record came from a bulk archive import. If it’s yours, link it to your profile.
Abstract (EN)
Prostate cancer is a severe cancer type which kills a large number of males every year. The new nanotechnological therapeutic tools based on the targeting of the over-expressed receptors have showed advances to decrease the side effects on healthy cells. In this thesis, gold nanoparticles were synthesized using mannan (M-AuNPs), which is a polymer of mannose, attaches the mannose 6-phosphate receptor (M6PR) highly expressed in prostate cancer. AuNPs were used as anticancer drug delivery vehicle and their efficiency was compared with other gold nanoparticles reduced with starch and citrate on healthy PNT1A and cancerous DU145 cells. The results showed that the synthesized AuNPs did not influence the viability of the both cell lines. Dox-loaded AuNPs displayed a high rate of toxicity on DU145 cancer cells by inducing cell cycle arrest in G2/M phase. As a conclusion, M-AuNPs can be a promising tool for prostate cancer by combining with photothermal therapy.
Author
Nur Selin Kaya
How to Cite
Nur Selin Kaya (Master Thesis). Effect of mannan-reduced gold nanoparticles on prostate cancer cells, 2016, Yeditepe University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)